Anti-GPRC5D Antibody for Cancer Treatment

ChangeBridge: Patent Apps - Peptides (C07K)

Published December 28th, 2022

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085114A1) filed by Kyinno Biotechnology Co., Ltd. The application describes an anti-G protein-coupled receptor family class C group 5 member D (GPRC5D) antibody or fragment thereof for the treatment of tumors or cancers. It also details a bispecific antibody targeting GPRC5D and CD3.

View original document View source feed page

What changed

This document is a publication of a patent application filed by Kyinno Biotechnology Co., Ltd. The application, identified as US20260085114A1, details an antibody or antibody fragment targeting GPRC5D, intended for the treatment of tumors and cancers. It also describes a bispecific antibody that targets both GPRC5D and CD3.

As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signifies potential future developments in cancer therapeutics and may be relevant for companies operating in the oncology and biotechnology sectors for competitive intelligence and intellectual property landscape monitoring.

Source document (simplified)

← USPTO Patent Applications

ANTI-GPRC5D ANTIBODY AND USE THEREOF

Application US20260085114A1 Kind: A1 Mar 26, 2026

Assignee

Kyinno Biotechnology Co., Ltd.

Inventors

Jinying Ning, Hao Peng, Feng Hao, Feng He

Abstract

Provided is an anti-G protein-coupled receptor family class C group 5 member D (GPRC5D) antibody or a fragment thereof. Also provided is the use of the antibody or fragment thereof as an active ingredient for treatment of tumors or cancers. In addition, further provided is a bispecific antibody comprising the antibody or fragment thereof and aiming at GPRC5D and CD3.

CPC Classifications

C07K 16/2809 A61K 38/00 A61P 35/00 C12N 15/11 C07K 2317/24 C07K 2317/31 C07K 2317/51 C07K 2317/515 C07K 2317/522 C07K 2317/524 C07K 2317/526 C07K 2317/565 C07K 2317/732 C07K 2317/92